Glaukos (GKOS) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
383.5M
Gross Profit
289.5M
75.48%
Operating Income
-108.1M
-28.20%
Net Income
-146.4M
-38.17%
EPS (Diluted)
-$2.77
Balance Sheet Metrics
Total Assets
974.8M
Total Liabilities
207.8M
Shareholders Equity
766.9M
Debt to Equity
0.27
Cash Flow Metrics
Operating Cash Flow
-70.3M
Free Cash Flow
-67.6M
Revenue & Profitability Trend
Glaukos Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 383.5M | 314.7M | 282.9M | 294.0M | 225.0M |
| Cost of Goods Sold | 94.0M | 75.6M | 69.0M | 66.6M | 91.7M |
| Gross Profit | 289.5M | 239.1M | 213.9M | 227.4M | 133.2M |
| Operating Expenses | 397.6M | 362.8M | 316.2M | 280.3M | 256.8M |
| Operating Income | -108.1M | -123.7M | -102.3M | -52.9M | -123.6M |
| Pre-tax Income | -145.6M | -133.7M | -98.4M | -49.3M | -132.3M |
| Income Tax | 771.0K | 934.0K | 766.0K | 326.0K | -12.0M |
| Net Income | -146.4M | -134.7M | -99.2M | -49.6M | -120.3M |
| EPS (Diluted) | -$2.77 | -$2.78 | -$2.09 | -$1.07 | -$2.70 |
Income Statement Trend
Glaukos Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 449.8M | 395.5M | 443.9M | 486.1M | 469.4M |
| Non-Current Assets | 525.0M | 545.0M | 558.5M | 563.6M | 536.1M |
| Total Assets | 974.8M | 940.4M | 1.0B | 1.0B | 1.0B |
| Liabilities | |||||
| Current Liabilities | 75.1M | 74.0M | 72.4M | 63.4M | 49.7M |
| Non-Current Liabilities | 132.7M | 404.6M | 400.0M | 399.2M | 288.4M |
| Total Liabilities | 207.8M | 478.6M | 472.4M | 462.5M | 338.1M |
| Equity | |||||
| Total Shareholders Equity | 766.9M | 461.8M | 530.0M | 587.2M | 667.4M |
Balance Sheet Composition
Glaukos Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -146.4M | -134.7M | -99.2M | -49.6M | -120.3M |
| Operating Cash Flow | -70.3M | -56.4M | -41.5M | 12.0M | -11.4M |
| Investing Activities | |||||
| Capital Expenditures | -6.3M | -20.2M | -30.1M | -47.8M | -6.9M |
| Investing Cash Flow | 47.8M | 14.1M | 44.8M | -58.2M | -205.1M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 44.8M | -4.0M | -3.0M | 8.3M | 238.3M |
| Free Cash Flow | -67.6M | -78.0M | -63.3M | -23.1M | -29.9M |
Cash Flow Trend
Glaukos Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-37.81
Forward P/E
-93.12
Price to Book
7.61
Price to Sales
14.47
PEG Ratio
-93.12
Profitability Ratios
Profit Margin
-30.57%
Operating Margin
-19.39%
Return on Equity
-20.36%
Return on Assets
-6.68%
Financial Health
Current Ratio
6.49
Debt to Equity
14.09
Beta
0.81
Per Share Data
EPS (TTM)
-$2.27
Book Value per Share
$13.46
Revenue per Share
$7.42
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| gkos | 5.9B | -37.81 | 7.61 | -20.36% | -30.57% | 14.09 |
| Abbott Laboratories | 233.3B | 17.42 | 4.78 | 30.65% | 31.89% | 27.09 |
| Boston Scientific | 154.3B | 75.79 | 6.91 | 9.50% | 11.58% | 52.16 |
| Masimo | 8.8B | 129.16 | 9.35 | -25.07% | -23.25% | 72.01 |
| Globus Medical | 7.7B | 42.44 | 1.88 | 4.63% | 7.39% | 2.27 |
| Bio-Rad | 7.1B | -3.83 | 1.03 | -27.52% | -85.16% | 20.50 |
Financial data is updated regularly. All figures are in the company's reporting currency.